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INTRODUCTION
The Charcot-Marie-Tooth (CMT) diseases (hereditary motor and
sensory neuropathies) are the most frequent genetic disorders of
the peripheral nervous system, affecting up to 1 in 2500 people
(Skre, 1974). The CMT diseases are heterogeneous, manifesting
with, among other features, distal muscle weakness and atrophy,
and impaired sensation. One clinically useful grouping of CMTs is
into primary demyelinating or axonal pathology. Demyelinating
forms have a profound reduction in nerve conduction velocity
(NCV), whereas CMTs resulting from primary axonal degeneration
show normal, or slightly reduced, NCV but decreased amplitude
of the compound muscle action potential or sensory nerve action
potential (Antonellis et al., 2003). The hereditary motor
neuropathies (HMNs) are related diseases involving degeneration
of lower motor neurons, leading to muscle wasting. CMT type 2D
(CMT2D) and distal spinal muscular atrophy type V
(dSMAV/HMNV) are autosomal dominant disorders that generally
result in slowly progressing weakness and atrophy, with focal
wasting of the musculature.
Families segregating CMT2D and dSMAV were found to have
causative mutations in the gene encoding glycyl-tRNA synthetase,
GARS (Antonellis et al., 2003). GARS is an aminoacyl-tRNA
synthetase: a group of evolutionary conserved enzymes that are
essential for translation because they catalyse the addition of an
amino acid to its cognate tRNA for protein synthesis. GARS is
expressed ubiquitously and functions as a homodimer (Shiba et al.,
1994; Williams et al., 1995).
Genetic and phenotypic screens have shown that different GARS
mutations present a clinical continuum of predominantly distal
motor neuronopathy/axonopathy with mild to moderate sensory
loss, varying within and between families (Sivakumar et al., 2005;
Del Bo et al., 2006; Dubourg et al., 2006; James et al., 2006).
Typically, the first symptom is muscle weakness in the hands, which
develops at between 8 and 36 years of age; the involvement of the
lower extremities varies.
Seburn and colleagues reported the mouse mutant GarsNmf249;
these mice have severe sensory and motor axonal neuropathy, and
die by 6-8 weeks of age (Seburn et al., 2006). GarsNmf249/+ mice have
abnormal neuromuscular junctions and muscle force. They have
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SUMMARY
Mutations in the enzyme glycyl-tRNA synthetase (GARS) cause motor and sensory axon loss in the peripheral nervous system in humans, described
clinically as Charcot-Marie-Tooth type 2D or distal spinal muscular atrophy type V. Here, we characterise a new mouse mutant, GarsC201R, with a point
mutation that leads to a non-conservative substitution within GARS. Heterozygous mice with a C3H genetic background have loss of grip strength,
decreased motor flexibility and disruption of fine motor control; this relatively mild phenotype is more severe on a C57BL/6 background. Homozygous
mutants have a highly deleterious set of features, including movement difficulties and death before weaning. Heterozygous animals have a reduction
in axon diameter in peripheral nerves, slowing of nerve conduction and an alteration in the recovery cycle of myelinated axons, as well as innervation
defects. An assessment of GARS levels showed increased protein in 15-day-old mice compared with controls; however, this increase was not observed
in 3-month-old animals, indicating that GARS function may be more crucial in younger animals. We found that enzyme activity was not reduced
detectably in heterozygotes at any age, but was diminished greatly in homozygous mice compared with controls; thus, homozygous animals may
suffer from a partial loss of function. The GarsC201R mutation described here is a contribution to our understanding of the mechanism by which
mutations in tRNA synthetases, which are fundamentally important, ubiquitously expressed enzymes, cause axonopathy in specific sets of neurons.
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reduced nerve conduction velocities, with a loss of large diameter
peripheral axons, but no myelination defects. A loss-of-function
allele, GarsXM256, resulting from a gene-trap insertion, shows no
dominant phenotype; therefore, the GarsNmf249 phenotype is not
caused by a simple haploinsufficiency and may result from a gain
of function (Seburn et al., 2006).
In this study, we report a new mouse mutant, GarsC201R, which
gives rise to a less severe phenotype than GarsNmf249, and which
has locomotor and sensory deficits. Heterozygous animals show
reduced grip strength that is modulated by genetic background, a
reduction of axon diameter in peripheral nerves, slowing of nerve
conduction and an alteration in the recovery cycle of myelinated
axons; altered muscle characteristics and innervation are also seen,
although these are no obvious defects in the motor neurons. We
are able to produce homozygous mice, but these mice die by
postnatal day 17 with gait disturbance, loss of large diameter axons
and other neurological changes. GARS enzyme activity in the brains
of GarsC201R/+ mice is not significantly different from in wild-type
mice but, unexpectedly, is reduced by 60% in the homozygotes when
compared with wild-type controls. The GarsC201R mouse is a
valuable resource that provides an insight into the mechanism of
axonopathy resulting from mutations in this ubiquitously expressed
aminoacyl-tRNA synthetase.
RESULTS
Origin of GarsC201R mice and phenotype on two genetic
backgrounds
Two male F1 (C3H  BALB/c) mice were identified during a
routine screen in a large ENU (N-ethyl-N-nitrosourea) mutagenesis
project at the Medical Research Council (MRC) Mammalian
Genetics Unit (Nolan et al., 2000). The animals were siblings, F1
progeny of a BALB/cAnN G0 mutagenised male crossed to a
C3H/HeH female, and had deficits in grip strength, locomotor
activity and rotarod when screened using the SHIRPA protocol at
6 weeks of age (data not shown) (Rogers et al., 1997; Rogers et al.,
2001). Frozen sperm from each sibling was used for in vitro
fertilisation of C3H/HeH females to produce a set of offspring
(termed the N2 progeny) from each F1 male; the litter sizes were
n=19 and n=26.
Based on the SHIRPA results from the founder siblings, we
adopted grip strength as a robust score for ‘affected’ and ‘unaffected’
status in the N2 mice and following generations (Rogers et al., 1997).
Because the cohorts of affected progeny of each sibling showed no
significant phenotypic differences from each other, and because
these cohorts were subsequently shown to carry the same mutation,
from here on we combine all progeny data into cohorts either with
the ‘GarsC201R’ mutation or without the mutation (the ‘wild-type
littermate control’ cohort). After the GarsC201R mutation had been
identified, the mutation status for all animals was confirmed
subsequently by genotyping. We bred the N2 progeny either by
backcrossing to C3H/HeH mice to create N3 and N4 animals, or
by backcrossing to C57BL/6J mice to create N1 and N2 mice. All
of the assays discussed here took place using these N3/N4 (C3H)
or N1/N2 (C57BL/6) cohorts, unless stated otherwise.
Heterozygous animals on both genetic backgrounds appear to have
a normal life span (living to at least 17 months of age).
The grip strength of all four limbs combined was assessed
longitudinally from 1-15 months of age. Animals were also weighed
and no significant differences in weight were seen between
heterozygous and wild-type animals with the same genetic
background (i.e. within either the N3/N4 C3H or N1/N2 C57BL/6
cohort). From 1-15 months of age, a significant reduction in grip
strength was seen in both male and female GarsC201R/+ mice
compared with sex-matched wild-type littermates on both C3H
and C57BL/6 backgrounds (Fig. 1; supplementary material Fig. S1).
For example, the mean grip strength of 3-month-old GarsC201R/+
males on the C3H background (n=11) was 123.9±7.4 units
compared with 205.5±6.3 units in male littermate controls (n=10),
an average reduction of 40%. However, the phenotype was
considerably more pronounced on the C57BL/6 background than
the C3H genetic background. At 3 months of age, the mean grip
strength of GarsC201R/+ males on the C57BL/6 background (n=23)
was 75.4±3.7 units compared with 177.1±7.5 in wild-type
littermates controls (n=14), a reduction of 57%. This indicates that
genetic modifiers segregating between the C3H/HeH and C57BL/6J
backgrounds are having a pronounced effect on phenotype.
The motor phenotype of GarsC201R/+ mice was defined further by
measuring performance in an assay for skilled motor function, the
mouse reaching and grasping test (MoRaG) (Tucci et al., 2007); this
test is used to assay fine motor control because in many species,
including the mouse, the capacity to modulate a motor pattern
according to the task is essential for adaptation to the environment.
MoRaG is used to assess forepaw reaching and grasping motor
phenotypes: briefly, over a number of sessions, mice are trained to
reach through a narrow opening with their forepaws to retrieve food
pellets. MoRaG revealed differences between GarsC201R/+ males
(n=9) and wild-type littermate controls (n=10) (with the C3H
background). Quantitative analysis showed a statistically significant
increase (P<0.05) in the latency to the first reaching (LFR), an
indication of decreased motor flexibility. Furthermore, the percentage
of errors in grasping food pellets was approximately 40% higher in
GarsC201R/+ mice compared with control mice; this difference was
evident in the first session and sustained (more than 30% higher)
during the second session (Fig. 1D-F). In the first session, no
significant difference in the accuracy in reaching the target was
observed between the two groups. However, in the second session,
the wild-type group showed a reduction in percentage errors, an
index of motor improvement, whereas GarsC201R/+ mice maintained
a low performance in both sessions. Thus, the GarsC201R/+ mice have
decreased motor flexibility and a diminution in fine motor control.
Homozygous GarsC201R/C201R mice
We carried out intercrosses of the GarsC201R/+ mice on both the C3H
and C57BL/6 backgrounds, generating N5/N6 and N3/N4 mice,
respectively. The C3H background (the milder phenotype) produced
seven GarsC201R/C201R mice out of a total of 60 progeny (12%); the
C57BL/6 background produced four GarsC201R/C201R mice out of a
total of 76 progeny (5%). Owing to unknown reasons, all
homozygous GarsC201R/C201R mice died by postnatal day 17 on the
C3H background and by day 15 on the C57BL/6 background. A
comparison of the weights of three male C3H homozygotes at 15
days of age showed an average weight of 3.1 grams compared with
an average of 8.0 grams in their male wild-type and heterozygote
littermates, a decrease of 61%. Homozygous animals were
distinguishable early on by their small size and greatly impaired limb
movement; this was so severe in some cases that animals were culled
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a few days after birth, according to UK animal welfare regulations,
because they were unable to move to suckle (supplementary material
Movies 1 and 2). Whole-mount neurofilament staining did not show
any obvious abnormalities in the peripheral nervous system of
heterozygotes at 12.5 days post coitum (dpc) (C. Ruhrberg, personal
communication); we have not looked at homozygotes.
Identification of the GarsC201R mutation
We undertook a candidate positional cloning approach to identify
the mutant locus. As both founder siblings and their progeny had
indistinguishable phenotypes on all of the tests carried out, they
probably carried the same mutation; nevertheless, there was a
formal possibility that different mutations could have arisen either
in the G0 BALB/c male and/or in the C3H female to which this
male had been crossed.
We carried out a genome scan, on the C3H background, with
13 affected N2 progeny from each of the two F1 siblings: 72
polymorphic genome-wide single-nucleotide polymorphisms
(SNPs) were genotyped and linkage was found to mouse
chromosome (Mmu) 6 at between 22 and 114 Mb, and 22 and 84
Mb, respectively (data not shown). To refine the mapping and
reduce the critical region, haplotype mapping of 61 and 29 affected
mice from each sibling cohort was carried out and recombinant
chromosomes indicated that the mutation must lie between 53 and
73 Mb, and 53 and 58 Mb, respectively. This region has homology
to human chromosome 7p15, which contains the GARS gene; the
mouse ortholog maps to 55 Mb on Mmu 6 [see the Online
Mendelian Inheritance in Man (OMIM) website,
www.ncbi.nlm.nih.gov].
Of the many candidate genes in the region, the Gars gene stood
out because mutation of this gene in humans can give rise to
locomotor deficits, as we described in the mice. Therefore, we
sequenced the mouse Gars gene and found a point mutation in a
BALB/c haplotype in exon 5. In both cohorts, the point mutation
was a T to C transition at base pair 456 that results in a non-
conservative cysteine to arginine substitution at residue 201. Thus,
the mutant phenotype of the founder siblings was almost certainly
derived from the same ENU-induced mutation as in their BALB/c
father. The mutation was designated GarsC201R and was not present
in BALB/c, C3H, C57BL/6 or any other strain sequenced, including
129/J, A/J, AKR/J, CD1, DBA/2J, FVB/J, LP/J, MOLF, NZW, PWK,
RIIIS, SJL, SM/J, SWR and VM.
Intercrossing heterozygous GarsC201R/+ mice with heterozygous
GarsXM256/+ mice (the loss-of-function gene trap allele) yielded a
total of 40 progeny with three of the expected genotypes (wild-
type, GarsC201R/+ and GarsXM256/+); however, the fourth expected
genotype, double heterozygotes (GarsC201R/XM256), was absent,
indicating non-complementation of the two alleles and embryonic
lethality, thereby providing evidence that the GarsC201R mutation
is causative for the phenotype.
This mutation at residue 201 lies within the highly conserved
catalytic domain of the protein and potentially within the acceptor
stem recognition site (Fig. 2) (Xie et al., 2007). This cysteine residue
is conserved across a diverse range of organisms from humans to
Drosophila and Arabidopsis (Fig. 2A). The GarsC201R mutation
creates a restriction enzyme digestion site for the enzymes HaeII
and HhaI, enabling a protocol to be designed for routine genotyping
using PCR and restriction fragment length polymorphism (RFLP)
analysis (see Methods). All animals that had previously been
scored as affected were genotyped and shown to carry the mutation;
all unaffected mice were wild-type at this locus.
GARS protein levels and enzyme activity
GARS protein expression levels were examined by probing western
blots of the homogenate of a standardised dissected portion of brain
that included the motor and sensory cortex (Fig. 3A). Homogenates
were made from wild-type, GarsC201R/+ and GarsC201R/C201R mice at
15 days of age on the C3H background, and from wild-type and
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Fig. 1. Motor deficits in GarsC201R/+ mice. Four-paw grip strength of
GarsC201R/+ male mice compared with sex-matched wild-type littermates.
(A) Mice with a C3H genetic background from 1 to 15 month of age. The
numbers of mice sampled varied with the time point: GarsC201R/+, n=5-11; wild-
type littermates, n=4-10. (B) Mice with a C57BL/6 background at 3 months of
age: GarsC201R/+, n=23; wild-type littermates, n=14. (C) Mean grip strength
values (units) for GarsC201R/+ and wild-type littermates at 3 months of age on
the C3H and the C57BL/6 genetic backgrounds. The average value of the
heterozygote grip strength is also shown as a percentage of its wild-type
littermate control cohort. (D-F) Reaching and grasping deficits in GarsC201R/+
male mice (n=9) compared with sex-matched wild-type littermates (n=10), as
detected by the MoRaG test. (D) The latency to the first reach (LFR) is the
response time for reaching within the first session; the percentages of errors
during reaching (E) and grasping (F) are shown for GarsC201R/+ and wild-type
controls. Levels of statistical significance are: *P<0.05 and **P<0.01.
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GarsC201R/+ mice at 3 months of age on the C3H and C57BL/6
backgrounds. Western blots of these homogenates were probed
with an antibody to mouse GARS. The membrane was then
stripped and reprobed with an antibody to β-actin as an internal
protein loading control. The signal from the autoradiograph bands
was quantified and the GARS levels normalised for β-actin (Fig.
3B,C). At 3 months, there was no significant difference in GARS
levels between wild-type and GarsC201R/+ brain homogenates in
either genetic background (supplementary material Fig. S2).
However, at 15 days of age, there were significant increases in
protein levels in both heterozygotes and homozygotes compared
with wild-type littermates (Fig. 3C). Heterozygotes showed an
increase of 3.8-fold compared with wild-type mice (P=0.014) and
homozygotes showed an increase of 8.2-fold compared with the
wild-types (P=0.034).
To investigate the possible molecular mechanisms of pathology,
GARS aminoacylation activity was assayed directly in homogenates
of the same dissected portion of brain from wild-type, GarsC201R/+
and GarsC201R/C201R mice on the C3H background at 15 days of age
(N5/N6 generation), and from wild-type and GarsC201R/+ mice on
both C3H (N5/N6) and C56BL/6 (N3/N4) backgrounds at 3
months of age. Assays were carried out blind to the genotype, which
was decoded afterwards.
The enzyme functions as a homodimer and, in our assay, we
found that GARS aminoacylation activity was not significantly
different between wild-type and heterozygous C3H mice at 15 days
and 3 months of age (Fig. 3D,E). However, the mean GARS activity
in 15-day-old C3H GarsC201R/C201R mice (n=3) was 3.4±0.8
pmole/mg/minute and thus was reduced by 60% in comparison
with the mean value of 8.5±0.4 pmole/mg/minute for wild-type
littermate controls (n=3) (P=0.01) (Fig. 3D). GARS activity was not
significantly different between wild-type and GarsC201R/+ mice on
the C57BL/6 background at 3 months of age (data not shown).
General histopathology
Haematoxylin and eosin (H&E)-stained sections of various tissues
were examined in the C3H background in three wild-type and six
heterozygote littermates at 17 months of age, and in two wild-types,
two heterozygotes and two/three homozygotes at 15 days of age.
No abnormalities were observed in the heart, lung, liver, kidney,
adrenal glands, skin or gut, although organ size was reduced (in
proportion to body size) in homozygotes compared with in
heterozygous and wild-type littermates.
Brain and spinal cord sections were stained with H&E, Luxol
Fast Blue-Cresyl Violet, and for glial fibrillary acidic protein and
choline acetyl transferase. No abnormalities, including
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Fig. 2. The GARS protein. (A) The mutated residue in the GarsC201R mouse is
highly conserved from mammals through to Arabidopsis. (B) Known
mutations in humans (in black) and mice (in red) are scattered throughout the
GARS protein; the mouse mutation marked as P278K/Y is the GarsNmf249
mutation reported by Seburn and colleagues (Seburn et al., 2006). Note that
there are discrepancies in the numbering of mutations in humans and mice –
the protein shown here is the full-length mouse protein (Ensembl peptide ID
ENSMUSP00000003572), which is the mitochondrial GARS; the cytosolic
protein is shorter because it starts with an internal ATG. The mouse mutations
are numbered according to the full-length form of the protein, whereas the
human mutations are numbered according to the cytosolic form (Seburn et al.,
2006). The GarsC201R mutation lies within the catalytic domain, as described by
Schimmel and colleagues (Xie et al., 2007).
Fig. 3. GARS anomalies in the GarsC201R mouse brain. Protein levels and
enzyme activities of GARS in dissected brain homogenates from wild-type,
GarsC201R/+ and GarsC201R/C201R mice at 15 days of age (n=3 for each cohort) and
from wild-type and GarsC201R/+ mice at 3 months of age (n=3 for each cohort);
all mice were on the C3H background. (A) The dissected region, within the
dotted lines, of 15-day- and 3-month-old GarsC201R/+ and wild-type littermate
brains, which includes the motor and sensory cortex (mouse atlas,
www.mbl.org/). (B) Western blot showing levels of GARS protein in wild-type,
heterozygous and homozygous littermates at 15 days of age. (C) Graph of
quantified data from the western blot, normalised to the β-actin control.
(D,E) Acylation activity of GARS in brain homogenates. (D) GARS activity in
homogenates of the dissected motor and sensory cortex of wild-type,
heterozygous and homozygous littermates at 15 days of age, and (E) wild-type
and heterozygotes at 3 months of age.
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demyelination or inflammation, were seen in heterozygous animals
at 17 months or 15 days of age.
In cross sections of 17-month-old GarsC201R/+ sciatic nerves
(n=3), we found a 50% reduction in the number of large diameter
axons compared with in wild-type littermates (n=3) (P=0.03)
(supplementary material Fig. S3A). To investigate potential motor
and/or sensory involvement, we went on to analyse a cohort of
heterozygous 3-month-old GarsC201R/+ mice with a C57BL/6
background and their wild-type littermates.
Assessment of hindlimb muscle force and muscle contraction
characteristics, and motor unit and motor neuron survival
In order to examine whether motor pathways were affected in
GarsC201R/+ heterozygotes, an in vivo physiological analysis of
muscle and motor function, and a morphological analysis of
hindlimb muscles and motor neuron survival were performed in
adult female GarsC201R/+ heterozygotes and sex-matched wild-type
littermate controls. The mice were examined at 4 months of age
(120 days), with a cohort size of n≥5 per cohort on the C57BL/6
background (N3/N4 generation). Each animal was weighed and,
by 120 days of age, female GarsC201R/+ heterozygote mice weighed
an average of 20.7±1.1 grams, which is significantly less than their
female wild-type littermates, which had an average weight of
23.5±0.6 grams (P=0.005). Thus, as the animals become more
inbred onto the C57BL/6 background, we see an effect on body
weight that is not significant in the more mixed background of the
N1/N2 generation, which was used for grip strength analysis.
To assess muscle force, we examined the maximum force of the
two hindlimb muscles: the tibialis anterior (TA) and the extensor
digitorum longus (EDL). In GarsC201R/+ mice, the TA had a
maximum twitch of 20.7±0.8 grams; this was significantly weaker
than the TA muscle force in wild-type littermates, which had a
maximum twitch force of 36.1±1.8 grams (P<0.001) (Fig. 4A). The
maximum tetanic force of TA muscles in GarsC201R/+ mice was also
significantly less than that in wild-type littermates, with the TA
muscles in GarsC201R/+ mice producing only 67.1±1.9 grams
compared with 125.1±2.8 grams in wild-type littermates (P<0.001)
(Fig. 4B). However, there was no significant difference in the force
output of the EDL muscles in GarsC201R/+ mice compared with wild-
type littermates. The EDL muscles of the GarsC201R/+ mice produced
a maximum twitch of 7.57±0.4 grams compared with 9.31±0.7
grams in wild-type littermates, and a maximum tetanic force of
21.8±1.2 grams compared with 24.6±1.7 grams in wild-types (data
not shown). Interestingly, we found that in the SOD1G93A mouse
model of amyotrophic lateral sclerosis (ALS), both the TA and EDL
are equally and severely affected by the end stage of the disease,
whereas the TA is affected more profoundly at the earlier stages
of the disease (Sharp et al., 2005). Therefore, it is possible that the
first signs of muscle wasting in GarsC201R/+ mice appear in TA
muscles and that they may be indicative of the appearance of late-
onset motor neuron pathology.
The preservation of force in the EDL muscles could be the result
of more efficient reinnervation by the remaining motor axons
following loss of connectivity, or it could simply be the result of
milder or non-existent denervation in this muscle compared with
the TA. In order to assess whether there were any physiological
signs of motor neuron degeneration in GarsC201R/+ mice, we
assessed the number of functional motor units that were
innervating the EDL muscles in GarsC201R/+ mice by stimulating
the sciatic nerve with electrical impulses of increasing intensity.
Representative examples of motor unit traces from the EDL muscles
of wild-type and GarsC201R/+ mice are shown in supplementary
material Fig. S4A,B, respectively, and the mean motor unit survival
in each group is summarised in supplementary material Fig. S4C.
We found no evidence of motor unit loss in 4-month-old
GarsC201R/+ mice, with an average of 39±1 motor units innervating
the EDL of GarsC201R/+ mice compared with an average of 37±1
motor units in the EDL muscles of the wild-type mice; this
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Fig. 4. Maximum TA muscle force and histopathological analysis of
muscle fibres in 4-month-old wild-type and GarsC201R/+ mice. The
maximum twitch (A) and tetanic (B) force (grams) generated by TA muscles
from wild-type (n=10) and GarsC201R/+ (n=10) littermates (***P<0.001). (C) The
weight of TA muscles from wild-type (n=10) and GarsC201R/+ (n=10) littermates
(***P<0.001). (D) Examples of TA muscle sections, stained for succinate
dehydrogenase, an indicator of oxidative capacity, from (left) wild-type and
(right) GarsC201R/+ mice. Bar, 70 μm. Histograms representing the mean size of
cross-sectional areas of TA muscle fibres (E) (***P<0.001) and the mean
number of TA muscle fibres (F) from wild-type (n=3) and GarsC201R/+ (n=3)
littermates. Errors bars represent the standard error of the mean (s.e.m.). The
data collected on muscle fibre sizes were sorted into frequency distribution
histograms (G).
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difference was not significant. We also examined whether the
phenotype of the EDL muscles was altered in GarsC201R/+ mice. EDL
muscles are normally fast muscles that fatigue rapidly when
stimulated repeatedly (see supplementary material Fig. S4D). We
established the response of EDL muscles to repetitive stimulation
in 120-day-old wild-type and GarsC201R/+ mice and found that the
responses were not significantly different (supplementary material
Fig. S4D,E, respectively). Furthermore, there was no change in the
fatigue index (F.I., the maximum muscle force at the end of a 3-
minute period of stimulation, expressed as a ratio of the maximum
force at the start of the test) of the EDL in GarsC201R/+ mice, which
had an F.I. of 0.77 compared with 0.74 in wild-type littermates
(supplementary material Fig. S4F), where an F.I. value approaching
1 indicates that a muscle is highly fatigable.
At the end of the physiological tests, the hindlimb muscles from
GarsC201R/+ mice and their wild-type littermates were removed and
weighed. The results showed that the muscle weakness observed in
GarsC201R/+ TA muscles was reflected in a significant reduction in
weight, so that TA muscles from GarsC201R/+ mice weighed on
average 32±0.64 milligrams compared with 46±1.48 milligrams in
wild-type mice (P<0.001) (Fig. 4C). TA muscles were also stained
for succinate dehydrogenase (SDH) activity. As shown in Fig. 4D, a
greater proportion of muscle fibres stain darkly for SDH in
GarsC201R/+ mice compared with control TA muscles. This is an
indication of a change in the phenotype of TA muscles in GarsC201R/+
mice, since increased staining for SDH shows the increased oxidative
capacity of these muscle fibres. In addition, GarsC201R/+ TA muscle
fibres appeared larger than those of wild-type littermate controls.
We therefore assessed the cross-sectional area (CSA) of TA muscle
fibres in SDH-stained sections of GarsC201R/+ mice (n=3) and wild-
type littermates (n=3). In GarsC201R/+ mice, the average CSA of TA
muscle fibres is 3130±28 μm2 compared with only 2292±14 μm2 in
controls (Fig. 4E). Thus, there is a significant increase in the CSA
of TA muscle fibres in GarsC201R/+ mice compared with in controls
(P<0.001). This hypertrophy of TA muscle fibres in GarsC201R/+ mice
is accompanied by a significant loss of muscle fibres so that, in
GarsC201R/+ mice, the average number of muscle fibres per muscle
section is only 1537±161 compared with 2694±122 in controls (Fig.
4F). Morphometric analysis of the size of muscle fibres reveals that
the TA muscles in GarsC201R/+ mice contain fewer small muscle
fibres, as shown in the frequency distribution histogram in Fig. 4G,
and a greater proportion of larger fibres than in the TA muscles of
wild-type littermates. These results are consistent with denervation
atrophy, leading to a decrease in fibre number, and compensatory
hypertrophy of the remaining fibres.
The weight and histochemical properties of EDL muscles were
also assessed. Although the EDL muscles in GarsC201R/+ mice
weighed less than those in littermate controls (8.58±0.27 grams
versus 7.79±0.29 grams, respectively), this reduction in muscle
weight was not significant. Histochemical analysis of the oxidative
capacity of EDL muscle fibres revealed that the EDL of GarsC201R/+
mice had a characteristic mosaic pattern of SDH staining. The
majority of muscle fibres in GarsC201R/+ mice stained lightly for
SDH, indicating that, similar to the EDL muscle fibres in wild-type
littermates, these fibres have a low oxidative capacity (data not
shown), consistent with little or no denervation in the EDL.
We also measured the CSA of EDL muscle fibres in SDH-stained
sections of EDL from GarsC201R/+ and wild-type littermates. As
observed in the TA, the EDL muscle fibres from the GarsC201R/+
mice were significantly larger than EDL muscle fibres in wild-type
littermates (supplementary material Fig. S4G). Furthermore, there
were fewer muscle fibres in the EDL muscle sections of GarsC201R/+
mice compared with controls (supplementary material Fig. S4H)
and, as shown in the size frequency distribution histogram, the
fibres that survive are larger than those in control mice
(supplementary material Fig. S4J). This is consistent with some
denervation, but at the level of individual terminals rather than
whole motor units.
To test whether the observed reduction in TA muscle force and
loss of muscle fibres in the GarsC201R/+ TA and EDL were the result
of motor neuron degeneration, the number of Nissl-stained motor
neurons present in the lumbar spinal cords was assessed. We
observed no motor neuron loss in the mutant mice, despite the
reduction in TA muscle force and the loss of TA and EDL muscle
fibres in these mice at the same age (see supplementary material
Fig. S4I). This is consistent with other Gars alleles in mice, in which
the pathology was in the distal axon and not evident in the spinal
cord or ventral roots.
The differential severity in the phenotype of the EDL versus the
TA is reflected in the innervation of the neuromuscular junctions
(NMJs). In wild-type mice, the EDL and TA both have typical NMJ
morphology, with a complex pretzel-shaped appearance and the
nerve terminal directly overlying the acetylcholine receptors
(AChRs) in the muscle membrane (Fig. 5A,B). In the GarsC201R/+
mice, the NMJs found on the EDL were, in some cases, fairly normal
and, in other cases, much smaller with a much less complex
geometry (Fig. 5C,D). In the TA, some NMJs had relatively normal
morphology, although regions of the receptor field were sometimes
unoccupied by the nerve terminal, and portions of the terminal
arbor appeared atrophied (Fig. 5E, blue arrow). Instances of clear
denervation were also observed, with some AChR patches
completely lacking presynaptic input (Fig. 5E, red arrow). The
frequency of such defects was significantly higher in the GarsC201R/+
TA, with 6.2±3.2% of the NMJs showing marked partial innervation
and 3.1±1.2% showing complete denervation compared with
1.6±1.1% and 0.3±0.5%, respectively, in the GarsC201R/+ EDL (P=0.08
and P=0.03, respectively, t-test; GarsC201R/+ EDL values were not
significantly different from those in control mice). This denervation
was muscle specific and an overall reduction in the number of
motor axons was not seen in large, primarily motor nerves such
as the motor branch of the femoral nerve, which innervates the
quadriceps. Control mice had 558±38 myelinated axons in this
nerve, whereas GarsC201R/+ mice had 559±29 (n=3 mice per
genotype, all mice were 5 months of age).
Assessment of sensory physiology and histopathology
To assess the properties of peripheral sensory neurons, we studied
the purely sensory saphenous nerve in five GarsC201R/+ mice and
three wild-type littermates on the C57BL/6 background. There was
no significant difference (P>0.3, t-tests) in the mean number of
myelinated axons (476±15 in GarsC201R/+ mice; 449±31 in wild-type
mice), with no sign of degenerating or demyelinated axons (Fig.
6A,B). However, quantification of axon diameters revealed a
significant shift in the axon calibre towards a smaller diameter in
the saphenous nerve of GarsC201R/+ mice compared with wild-type
littermate controls (Fig. 6C). Although there were 83±7 axons with
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a calibre of greater than 3.5 μm in the wild-type mice, this number
was reduced profoundly to 13±6 in GarsC201R/+ nerves (P<0.001, t-
test). Analysis of the hairy skin of the medial dorsum of the hindfoot,
corresponding to the innervations territory of the saphenous nerve,
and the glabrous skin, which is innervated by branches of the tibial
nerve, showed a normal dense plexus of axons in the subepidermis
and epidermis in both genotypes of mice (Fig. 6D,E). As epidermal
nerve fibre density is derived exclusively from unmyelinated (C-)
fibres, there is, therefore, no evidence for a loss of unmyelinated
sensory neurons.
Sensory nerve pathology
There were significant differences in the conduction velocity and
amplitude of the Aβ-fibre sensory nerve compound action potential
(SNAP) in GarsC201R/+ mice compared with wild-type littermates,
but there were no significant changes for unmyelinated (C-) fibres
(Fig. 7). Corresponding to the change in axon calibre of myelinated
fibres of the GarsC201R/+ saphenous nerve, the mean conduction
velocity of the Aβ-fibre SNAP was 33.4±0.6 milliseconds in wild-
type controls (n=8) compared with 23.4±0.8 milliseconds in mutant
mice (n=7) (P<0.001). There was also a small, but significant, drop
in the amplitude of the Aβ-fibre SNAP (wild-type, 1.7±0.2 mV;
GarsC201R/+, 1.2±0.2 mV; P<0.05) and a trend for a reduced
conduction velocity of the C-volley in mutant animals (wild-type,
0.98±0.04 ms; GarsC201R/+, 0.84±0.06 ms; P=0.057). In agreement
with a normal subepidermal and epidermal nerve fibre morphology,
there was no significant difference in the amplitude of the C-fibre
SNAP (wild-type, 312±60 μV; GarsC201R/+, 474±123 μV; P>0.2).
We used nerve excitability testing to determine the strength-
duration time constant, the recovery cycle, the threshold
electrotonus and the current-threshold relationship in four wild-
type mice and six GarsC201R/+ mice. There were clear differences
in the onset and magnitude of the superexcitability and the relative
refractory period (RRP) (Fig. 7C), but not in the recovery cycle
(Fig. 7D) or the other parameters tested (supplementary material
Fig. S5). For a period of approximately 200 milliseconds after an
action potential, there are profound changes in the excitability of
myelinated axons that manifest as refractoriness, superexcitability
and late subexcitability, which reflect nodal and paranodal
membrane properties. The balance of transient sodium and fast
potassium conductances influences superexcitability. It reflects
the net charge that is transferred to the internode (Bostock, 2004)
and is best studied following the recovery from a single
conditioning stimulus. By contrast, late subexcitability is
controlled by slow nodal potassium conductances (mainly by the
Disease Models & Mechanisms
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Fig. 5. NMJ morphology and nerve occupancy.
(A,B) NMJs in the EDL and TA of wild-type mice show
typical morphologies. In the GarsC201R/+ mice, NMJs in the
EDL have variable geometries with some being relatively
normal (C), whereas others were very small and much
less elaborate (D). (E) In the TA, regions of partial
innervation were observed (a subtle example is indicated
by the blue arrow) and portions of the terminal arbor
appear atrophied. Examples of clear denervation were
also observed (red arrow). Bar, 7 μm.
Fig. 6. Light microscopy of Toluidine Blue-stained, semi-thin resin section of
the saphenous nerve from 3-month-old wild-type littermate control (A) and
GarsC201R/+ mutant mice (B) on the C57BL/6 background. There is no axonal
loss, axon degeneration or demyelination, but quantification of axon diameters
(C) reveals a shift towards a smaller diameter in the GarsC201R/+ nerve. (D,E)
Confocal fluorescent images of the subepidermal (yellow arrows) and epidermal
(red arrows) axons innervating the glabrous skin of wild-type littermate control
(D) and GarsC201R/+ mutant (E) mice. Bars, 70μm (A,B); 25μm (D,E).
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M-current Kv7/KCNQ) (Schwarz et al., 2006) and is best seen
following application of a conditioning train of action potentials.
Corresponding to the delay of conduction velocity, there was a
change in the peak of the superexcitability (expressed as a
reduction of the threshold) from 2.48±0.31 milliseconds in wild-
type mice to 4.82±0.80 milliseconds in mutants (P=0.058), and
there was a prolongation of the relative refractory period from
1.0±0.1 milliseconds in wild-type controls to 2.2±0.2 milliseconds
in mutant nerves. Furthermore, there was a highly significant
reduction in the amplitude of the superexcitability from –36±3.5%
to –13±2.5% (P<0.001).
Central nervous system (CNS) histopathology of homozygous
GarsC201R/C201R mice
In 15-day-old GarsC201R/C201R mice, we saw potentially abnormal
phenotypes in motor areas of the cortex; the dorsal column of the
spinal cord; the dorsal root; and the trigeminal ganglia, when
compared with heterozygous and wild-type controls
(supplementary material Fig. S3B,C); however, sample sizes were
small. In the motor cortex, the cell numbers in layer III were
reduced [wild-type cell count, 117±13 cells per unit (n=2);
homozygote cell count, 74±12 cells per unit (n=3)]; this was not
statistically significant (P=0.09), which could be because of the low
numbers of mice sampled (supplementary material Fig. S3B).
Sensory cortex cell counts were similar between all three genotypes
(data not shown).
The mean average CSA of the thoracic dorsal column of
homozygotes appeared to be smaller than that of wild-type controls,
which would correlate with the small axon calibre found in the
dorsal roots of heterozygous animals (supplementary material Fig.
S3C); but, again, sample sizes were small.
DISCUSSION
We identified the GarsC201R founder mice in a phenotype-driven
screen that analysed a large set of ENU-mutagenised mice for novel
motor mutants. Positional cloning, using grip strength to score for
affected animals, led to the identification of a non-conservative
cysteine to arginine change in a highly conserved residue in the
GARS catalytic domain (Cader et al., 2007; Xie et al., 2007). The
effect on grip strength varied with genetic background, in
accordance with the variations in presentation seen in humans
(Antonellis et al., 2003; Dubourg et al., 2006; Sivakumar et al., 2005);
the GarsNmf249 mouse phenotype also varied depending on genetic
background (Seburn et al., 2006). Determining the genetic factors
that modulate GARS mutations may give us intervention points
for therapy, and the GarsC201R mouse could be an excellent model
in which to find such modifying loci. Intriguingly, a recent paper
(Mozhui et al., 2008) has defined a region (Qrr) on distal mouse
chromosome 1 that modulates the gene expression of more than
half of all aminoacyl-tRNA synthetases in CNS tissues, and the
effect on Gars is particularly strong – the C57BL/6 trans-
quantitative trait loci (QTL) allele of Qrr has a positive additive
effect and consistently increases Gars gene expression by 10-30%.
Human GARS mutations cause strikingly selective atrophy,
weakness and corresponding abnormal neurophysiological profiles
of the thenar musculature, with sparing of the adjacent muscles
that are innervated by the same segment (for example, the
hypothenar musculature). In our studies, the overall picture of the
dmm.biologists.org366
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Fig. 7. Testing conduction velocity and
amplitude. (A) Schematic representation
of the setup for nerve excitability testing
of the saphenous nerve. (B) Stimulus
paradigm for recording the recovery cycle.
A single supramaximal conditioning
stimulus or a train of seven conditioning
stimuli is followed by the test stimulus at a
variable latency of 0.7 to 200 milliseconds.
(C) In animals carrying the GarsC201R
mutation, the magnitude of the
superexcitability is lower and later in the
recovery cycle, and the relative refractory
period is longer compared with in wild-
type controls. Using a single conditioning
stimulus, superexcitability is defined as the
decrease of the threshold below the line of
neutrality (0 on the ordinate). The
magnitude of the maximal threshold
reduction is marked for wild-type (red
arrow) and GarsC201R/+ (blue arrow) by
vertical arrows. The relative refractory
period is defined as the time between zero
and the point at which the excitability
threshold crosses the line of neutrality. The
horizontal arrows show this time period:
wild-type (red arrow) and GarsC201R/+ (blue
arrow). (D) The magnitude (vertical arrows)
and peak time (horizontal arrows) of the
late subexcitability is not significantly
different.
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heterozygous mice is of clear histopathological and
electrophysiological deficits in the sensory system, together with
deficits in the function of some muscles that are consistent with
neurological changes of the motor system; however, there were no
clear deficits in motor neurons at the ages studied. Thus, a detailed
longitudinal assessment of the motor system of these mice needs
to be undertaken. We found that there was a preferential
involvement of muscles, such that the large TA muscles were more
affected than EDL muscles. However, both muscles show a
significant loss of muscle fibres, accompanied by hypertrophy of
those muscle fibres that survive. In humans, affected individuals
generally have normal sensory, and slightly reduced motor (when
there is substantial axonal loss), nerve conduction velocities,
suggesting a primary axonal pathology (Del Bo et al., 2006;
Sivakumar et al., 2005). In contrast to humans, a reduction of
sensory (GarsC201R/+) and motor conduction velocity (GarsNmf249/+)
(Seburn et al., 2006) is found in the Gars mouse models. As
histological studies have failed to find signs of primary
demyelination in GarsC201R/+ mice, but have found a reduction of
axon calibre, the reduction in conduction velocity is best explained
by the dropout of the largest and fastest conducting axons. The
changes in the recovery cycle are consistent with this interpretation.
The muscle specificity of the phenotype is consistent with
human CMT2D. The defects seen in NMJ occupancy are much
milder than those observed previously in GarsNmf249/+ mice and,
when combined with the lack of axon loss even in distal nerves
such as the femoral motor branch, may indicate that the
degeneration in GarsC201R/+ mice occurs at the level of individual
motor neuron terminals, and not at the level of motor axons (motor
units). The percentages stated may be underestimates owing to
variability in antibody staining, the subtlety of the partial
innervation, and the fact that denervated muscle fibres may have
atrophied in 5-month-old mice, preventing their inclusion in this
analysis. As with the NMJ innervation, the relative preservation of
axon diameter and myelinated axon number, even in more distal
nerves, also indicates that the GarsC201R allele is much milder than
the GarsNmf249 allele. In this regard, the GarsC201R/+ mouse may
present a more accurate model of human CMT2D. An intriguing
question to be addressed in this mouse model is, how much of the
phenotype occurs as a developmental defect and how much arises
later from degeneration? We note that we see relatively little loss
of function over time in the grip strength analysis and, thus, at least
a component of the phenotype probably arises early in the life of
the animal; although, only a detailed longitudinal study of motor,
sensory and muscle phenotypes could determine if the mutation
results in developmental and/or degenerative changes. We note that
we have studied the GarsC201R mutation on two inbred mouse
backgrounds that clearly give rise to different phenotypes. The
results of GARS mutations in humans are highly variable, ranging
from asymptomatic individuals at over 40 years of age to severe
infantile disease (Dubourg et al., 2006; James et al., 2006); thus,
both human and mouse manifest variable severity arising from
different alleles and genetic backgrounds.
We produced homozygotes that, for the first time, show the
effects of having two copies of a Gars point mutation; the mild
phenotype found in heterozygous animals becomes a pre-weaning
lethal disorder, resulting in what appear to be extensive deficits in
the brain and spinal cord in homozygotes. We found no differences
in protein levels (by western hybridisation) between adult
heterozygous and wild-type mice at 3 months of age, but a
significant increase in protein levels in heterozygotes and
homozygotes at 15 days of age compared with in wild-types. This
may indicate that the level of GARS is more crucial during
development than in adult mice; clearly the developmental profile
of this enzyme warrants further investigation. We note that no
difference in GARS protein levels was found between
lymphoblastoid cell lines from a human GARSG240R/+ heterozygous
patient and a wild-type individual (Antonellis et al., 2006); this is
similar to our findings for adult GarsC201R/+ heterozygous mice
compared with wild-type mice.
We found a 60% reduction in enzyme activity in the dissected
brain homogenate of homozygous mice (15 days of age), but no
significant difference between wild-type and heterozygous animals
at 15 days or 3 months of age; however, there was a trend towards
reduced enzyme activity in the heterozygotes compared with the
wild-type mice. The rise in protein levels in homozygous and
heterozygous animals at 15 days of age may be compensation for
reduced enzyme activity, possibly during a crucial developmental
window. The GARSC201R mutation impairs enzyme function but
our data also suggest that wild-type–GARSC201R heterodimers
retain more activity compared with mutant homodimers. Further
work is required to determine the extent of heterodimer formation
and the effects of GARSC201R on heterodimeric and homodimeric
enzyme activity (Nangle et al., 2007). The non-viability of
compound heterozygote mice carrying both the gene trap loss-of-
function GarsXM256 allele and either the GarsC201R allele or the
GarsNmf249 allele with fully retained activity (both compound
heterozygotes were embryonic lethal), suggest that there may be
functional interactions between wild-type and mutant proteins)
(Seburn et al., 2006).
A dominant negative activity or partial loss of function of the
GarsC201R allele is possible; this is supported by the increase in
phenotypic severity with increased dosage in either homozygotes
or in the absence of wild-type homodimers. However, a gain-of-
function mechanism cannot be dismissed for heterozygous mice,
since the overall activity of GARS is preserved in tissues. Structural
studies have revealed that the GARSNmf249 mutation and a majority
of the reported human GARS mutations affect the dimer interface,
sometimes through distant interactions, resulting in increases and
decreases in dimerisation; however, it remains unclear how this
relates to disease pathogenesis (Cader et al., 2007; Xie et al., 2007).
Chihara and colleagues found that Drosophila models, which had
previously been used to describe human GARS mutants, have loss-
of-function properties (Cader et al., 2007; Chihara et al., 2007);
furthermore, studies in yeast have also demonstrated loss-of-
function effects for some GARS mutants, but no dominant negative
effects (Antonellis et al., 2006). However, studies of aminoacylation
activity do not support a straightforward loss-of-function
mechanism since there is no correlation between the CMT
phenotype and enzyme activity (Nangle et al., 2006). Nevertheless,
mutant GARS proteins have aberrant distributions within cells
(Antonellis et al., 2006) and reduced expression in the neurite
periphery (Nangle et al., 2006).
Drosophila with mutations in the gars, tryptophanyl-tRNA
synthetase (wars) or glutaminyl-tRNA synthetase (qars) genes show
that cytosolic tRNA synthetase activities are needed for axonal
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maintenance during development, but that mitochondrial tRNA
synthetase activities have a greater role in maintaining dendrites
in adults (Chihara et al., 2007). The Drosophila mutations are loss-
of-function alleles and, unlike the mouse and human mutations,
all were recessive. Mutations in other aminoacyl-tRNA synthetases
are now starting to be described and may help our understanding
of how aberrations in these ubiquitous housekeeping enzymes
result in specific pathologies within the nervous system (Edvardson
et al., 2007; Scheper et al., 2007). Mutations in the human tyrosyl-
tRNA synthetase (YARS) gene were found to cause dominant
intermediate CMT type C, possibly owing to a partial loss of
enzyme activity giving rise to pathology at the neuron endings
(Jordanova et al., 2006). In the mouse, a recessive mutation in the
alanyl-tRNA synthetase (Aars) gene causes cerebellar Purkinje cell
loss and ataxia, probably because of a partial loss of the editing
function of the enzyme, leading to a low level of amino acid
misincorporation and, hence, protein misfolding and
neurodegeneration (Lee et al., 2006). In cultured human cells, a
mutant form of the valyl-tRNA synthtase (VARS) protein with
defective editing ability caused cell death (Nangle et al., 2006).
All of the GARS point mutations described so far in mice and
humans are dominant, implying that the phenotypes arise from
either a dominant gain-of-function mutation or haploinsufficiency.
Drosophila and mouse studies suggest that, depending on the
individual mutation, both of these causes are possible (Chihara et
al., 2007; Seburn et al., 2006). From our studies, either mechanism
is possible, and we also suggest another scenario in which the
phenotype could arise from a loss-of-function mutation (such as
loss of enzyme activity, as seen in the homozygous GarsC201R/C201R
mice) and a gain-of-function mutation, as suggested in the
GarsNmf249 model (Seburn et al., 2006); different pathological
mechanisms may be crucial at different time points in both
heterozygotes and homozygotes, that is, there could be a gain of a
new function leading to a toxic effect, combined with a loss of
function.
In terms of the effects on GARS function, loss of enzyme activity
might directly affect local translation, which is essential for axon
guidance, synaptic plasticity, cell migration, cell polarity, and other
areas of development and maintenance of the nervous system
(Giuditta et al., 2002; Jordanova et al., 2006; Lin and Holt, 2007;
Nangle et al., 2007; Park et al., 2008). Alternatively, it has been
postulated that GARS mutations could result in phenotypes either
because of a defect in translating proteins that contain glycine or
because the mutations affect a glycine-rich subset of proteins in
neurons (Antonellis et al., 2003); in fact, a set of cytoskeleton-
associated proteins (CAPs) and motor proteins involved in axonal
transport contain a glycine-rich CAP-Gly motif that binds to
microtubules during long-range transport (Li et al., 2002; Sivakumar
et al., 2005; Weisbrich et al., 2007). We carried out a search for this
motif in the human genome (by looking for protein sequences
containing the motif ) and found that fewer than ten proteins
contain it, suggesting that aberrations in the translation of this CAP-
Gly motif are unlikely to be causative of the phenotypes because
relatively few proteins carry it; however, we do not have information
on how crucial the individual levels of each of these ten proteins
are within neurons. Intriguingly, mutations in the CAP-Gly motif
in dynactin p150 and in tubulin-specific chaperone B are known
to cause peripheral motor neuron degeneration in humans and mice
(Li et al., 2002; Martin et al., 2002; Puls et al., 2003; Sivakumar et
al., 2005). Furthermore, we note that TAR DNA binding protein
(TDP-43), which causes cases of ALS, contains a glycine-rich
domain (Banks et al., 2008).
However, although aminoacylation is the only known function
for GARS, a wide range of non-canonical functions has been shown
for other aminoacyl-tRNA synthetases, including an involvement
in splicing, apoptosis, transcription, protein folding, and trafficking
(Park et al., 2005; Park et al., 2008; Jia et al., 2008; Ribas de Pouplana
and Geslain, 2008). Thus, it is possible that heterozygous and/or
homozygous phenotypes do not arise from defects in translation,
but arise because of aberrations in other, unknown, functions of
GARS.
METHODS
Wherever possible, all of the methods described below were
undertaken blind to mouse genotype, which was decoded after the
results were collected.
Mice
The GarsC201R mutation arose in an ENU mutagenesis experiment
at the MRC Mammalian Genetics Unit, Harwell, UK (Nolan et al.,
2000). A G0 mutagenised BALB/cAnN male produced two male
siblings, MUTN/610.6c and MUTN/610.6d and sperm from these
animals was used for in vitro fertilisation of C3H/HeH females in
the stock matings GENA201 and GENA202, respectively. As ENU
works on spermatagonial stem cells, one treated mouse may
produce multiple progeny derived from the same mutation in the
same stem cell. The resulting N2 progeny were backcrossed to
C3H/HeH or C57BL/6J mice. Intercrosses to produce homozygous
animals were carried out as described in the text. All animal studies
were carried out under the guidance issued by the MRC on
‘Responsibility in the use of animals for medical research’ (1993)
and under licence from the UK Home Office.
Grip strength testing
The grip strength test assessed neuromuscular function by
measuring, with an electronic digital force gauge, the peak amount
of force an animal applied in grasping a 108 centimetre wire grid
attached to a pull bar (Bioseb Instruments). The mouse was placed
on the flat wire grid connected to the force gauge and held on with
front and hindpaws. The mouse was held by the base of the tail
and was gently pulled away from the grid until it released its grip,
at which point the peak tension on the pull bar was recorded. The
mean of five measurements was determined for each mouse on
each day of testing. Further details of the standard operating
procedure for grip strength that we followed can be found at the
Eumorphia site http://empress.har.mrc.ac.uk/browser/.
Mice were scored as affected if their mean measure differed by
more than three standard deviations from the mean score for a
cohort of age- and sex-matched wild-type controls that had been
bred onto the same genetic background (C3H/HeH or C57BL/6J)
at the same generation.
MoRaG performance
We tested nine male GarsC201R/+ mice and ten male wild-type
littermate controls in two MoRaG test sessions over two
consecutive days. All mice were bred onto the C3H/HeH genetic
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background. The MoRaG test is a phenotyping assay that was
created to characterize fine motor behaviours in the mouse (Tucci
et al., 2007). The apparatus consists of a Plexiglas chamber with a
feeding platform on the outside front wall. Mice are primed to
perform in the task by restricting access to food for up to 16 hours
before the task. Prior to commencing the task, mice were placed
in the apparatus for a 5-minute acclimatisation period. Small food
pellets were then placed on the feeding platform at a distance of
approximately 1.5 centimetres. As the opening is not large enough
for the mouse to collect the food pellet using its mouth, the mouse
learns to use one or both forelimbs. Each trial began when the pellet
was delivered to the feeding platform and ended when the mouse
collected it. The intertrial interval varied from between 10 and
20 seconds. Performance in the task was assessed using
semiquantitative and quantitative parameters [see Tucci et al. (Tucci
et al., 2007) for a complete list of the parameters]. Semiquantitative
parameters were selected from a wide range of abnormalities that
may affect neurological, neuromuscular and behavioural function
(e.g. tremor, speed of movement, body and shoulder position,
posture). Three quantitative behaviours were also recorded: (1)
reaction times to reach the food pellets; (2) reaching accuracy; (3)
grasping accuracy. The LFR is an index of flexibility of the mouse
in changing from a default motor response (e.g. nose poking) to a
novel motor pattern (limb movement). Each session consisted of
30 consecutive trials lasting approximately 15-20 minutes in total.
Reaction times from the first ten trials were recorded. The MoRaG
data were analysed using the SPSS statistical package (SPSS,
Chicago, IL). Reaction times and LFRs within the session were
analysed by an analysis of variance (ANOVA) test.
Genetic mapping
To map the GENA201 and GENA202 mutations, N3 mice from
the C3H backcross were assessed for grip strength and scored as
affected by the criterion above. A whole genome scan using 72 SNPs
that were polymorphic between the C3H and BALB/c strains and
that were spaced every 20-40 Mbs across the 19 autosomes was
performed on 13 affected GENA201 and 13 affected GENA202
heterozygotes. For GENA201 mice, linkage was found to
chromosome 6 at between 22 Mb and 114 Mb, and for GENA202
mice, linkage was found between 22 Mb and 84 Mb, as stated in
the text. The critical region was narrowed by using a higher density
set of polymorphic microsatellite markers [D6Mit273 (46 Mb),
D6Mit183 (53 Mb), D6Mit384 (55 Mb), D6Mit186 (73 Mb),
D6Mit188 (75 Mb)] to haplotype map 61 affected animals, from
both the C3H (N3) and C57BL/6 (N2) background, for GENA201
and 29 affected mice, from both the C3H (N3) and C57BL/6 (N2)
background, for GENA202. Results from this haplotype analysis
showed that the mutation must lie within a BALB/c-derived critical
region defined by SNPs and a microsatellite at 53.8 Mb (refSNP
ID: rs3023070) and 73 Mb (D6Mit186) for GENA201 and at 53.8
Mb (refSNP ID: rs3023070) and 58.5 Mb (refSNP ID: rs13478778)
for GENA202 mice (all mapping positions are based on the mouse
genome sequence in NCBI Build 36, http://www.ncbi.nlm.nih.gov).
The GENA202 critical region between 53.8 and 58.5 Mb contained
63 genes (NCBI Build 36), including Creb5, Chn2 and Neurod6,
which are known to be involved in neuronal function and/or have
neuronal phenotypes when mutated. However, other than Gars,
none of the genes in the critical region were likely to give rise to
the GENA201 or GENA202 phenotypes because of either the
expression pattern or the existing functional data. The complete
Gars gene (all 17 exons and associated splice sites) was sequenced
in GENA201 and GENA202 mice, and the same mutation was
found in exon 5, conferring a non-conservative amino acid change
on the protein in both cohorts of affected mice.
Sequence analysis and routine genotyping
DNA was extracted from mouse tail tips using a genomic DNA
isolation kit (Promega UK Ltd). A primer pair per exon was used
for PCR amplification of the 17 exons of the Gars gene in wild-
type, heterozygous and homozygous mutant DNA from GENA201
and GENA202 mice. DNA sequences were resolved on an
automated MegaBACE 1000 DNA analysis system (Amersham
Pharmacia) and the base pair change in exon 5 was found. This
mutation introduces a restriction site for the enzymes HaeII and
HhaI, allowing a protocol to be designed for routine genotyping
by PCR followed by RFLP analysis. Routine genotyping: PCR
primers (forward: 5-CACGTGCTTGCTCTAGCAAGA-3;
reverse: 5-GTCTACCACTGAACACAGTCC-3) that are
complementary to regions within intron 4 and intron 5, respectively,
and thus span exon 5 of the Gars gene, were used to amplify a 420
bp product. This amplicon was digested with HhaI to give
fragments of 420 bp (there is no restriction site in the Gars loci of
wild-type BALB/c, C3H and C57BL/6 mice) and of 250 bp and 170
bp (Gars201R mutant gene).
Western hybridisation and enzyme activity
Mice from the C3H backcross were from generation N5 or N6 and
mice from the C57BL/6 backcross were from generation N3 or N4.
Mice were killed according to UK Home Office regulations and
brains were removed, dissected and the motor/sensory cortex-
containing region was flash frozen in liquid nitrogen. 10 mg of brain
per ml of buffer [50 mM Tris pH 7.5, 25 mM KCl, 1% NP40, 10%
glycerol, 1 mM DTT, 10 μl protease inhibitor cocktail (Sigma) per
ml] was homogenised using a plastic mortar and then centrifuged
in a microcentrifuge for 20 minutes at 12,000 rpm at 4°C.
Supernatant was aliquoted into 100 μl samples and stored at –80°C
until used. The protein concentration of a supernatant sample from
each brain was determined using a bicinchoninic acid assay (Pierce).
Homogenates were electrophoresed on polyacrylamide-Tris gels
(16% or 4-20% gradient) and then transferred onto a polyvinylidene
difluoride (PVDF) membrane (ImmobilonP). Membranes were
washed for 1 hour in blocking solution (5% w/v skimmed milk
powder, 0.05% Tween 20 in PBS), before addition of the anti-GARS
antibody (a gift from Kevin Talbot) in blocking solution at 4°C
overnight. The primary antibody was detected using AP-conjugated
anti-rabbit IgG (Sigma) and the results visualised using CPD-Star
(Roche). The blots were then stripped and reprobed using an
antibody against β-actin (Sigma A5441). Autoradiographs were
quantified using Imagemaster 1D software (Amersham Pharmacia
Biotech) and the GARS levels normalised for β-actin levels.
The same dissected brain protein homogenates were used to
measure GARS enzyme activity (Dignam and Dignam, 1984). One
100 μl sample was assayed from each brain for GARS activity: the
sample was split into three aliquots of 20 μl each and each aliquot
was assayed for GARS activity. To measure GARS activity, 60 μl of
reaction mix [10 μM glycine, 50 mM Tris pH 7.5, 25 mM KCl, 2 mM
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DTT, 10 mM magnesium acetate, 5 mM ATP, 2 μl RNAse inhibitor
(Ambion), 1 μM 3H-glycine (740 GBq/mMol, Amersham
Biosciences)] was added to each 20 μl brain supernatant sample
and the mix was incubated at 37°C for 20 minutes. 80 μM of tRNA-
bovine liver (Sigma) was added and the reaction was incubated for
a further 5 minutes at 37°C. The reaction mix was spotted on 3
MM Whatman filter paper and washed once in 10% trichloroacetic
acid (TCA) for 15 minutes, three times in 2.5% TCA for 15 minutes
and once, for a further 15 minutes, in 100% ethanol. The filter was
then air-dried and 5 ml of scintillation fluid (Ultima Gold,
PerkinElmer) was added. The samples were counted in a
scintillation counter, which reported the number of photons
detected as counts per minute (cpm). Each reaction mix was spotted
and counted three times. The difference between cpm and
disintegration per minute (dpm) is the efficiency of the counter in
detecting the release of β-particles. To obtain dpm, the mean of
each sample count was divided by the efficiency of the assay: dpms
were converted to disintegration per second and then divided by
the specific activity of the radioactive glycine to obtain pmoles. The
result was normalised using the protein concentration to obtain
pmoles per mg of protein per minute. For the negative control, the
reactions were processed as above, but no tRNA was added. For
the positive control, tryptophan activity was measured (3H-
tryptophan, 740 GBq/mMol, Amersham Biosciences) to check that
other aminoacyl transferases showed normal activity in the brain
homogenate. On the C3H background, tryptophan mean activity
in 3-month-old wild-type mice (n=5) was 52.6±5.4 pmole/mg/min
compared with 59.1±1.3 pmole/mg/min for GarsC201R/+ littermates,
and for 15-day-old C3H littermates, the activity was 48.6±2.5
pmole/mg/min for wild-type mice (n=3), 43.0±6.6 pmole/mg/min
for GarsC201R/+ mice (n=3) and 45.7±4.2 pmole/mg/min for
GarsC201R/C201R mice (n=3).
General histology
Organs (heart, lung, liver, kidney, adrenal gland, skin, gut and
skeletal muscle, including triceps, quadriceps and gastrocnemius
muscles) from three wild-type and six GarsC201R/+ mice at 17
months of age, and the whole carcass of two wild-type, two
GarsC201R/+ and three GarsC201R/C201R mice at 15 days of age, were
fixed in formalin, embedded in paraffin, cut into sections of 2-5
μm thickness, and stained with haematoxylin and eosin (H&E). All
mice were on the C3H background.
Brain and nerve histopathology and neuron counts
Brain and spinal cord (lumbar, thoracic and cervical levels) paraffin
sections were cut from the above group of mice; stained with H&E
and Luxol Fast Blue-Cresyl Violet; and immunostained for glial
fibrillary acidic protein and choline acetyl transferase. Neurons
from a 250750 μm area (1 unit) of the primary motor cortex were
counted and analysed using a Student’s two-tailed t-test.
Sciatic nerve sections were fixed in a solution of 4%
paraformaldehyde (PFA) at room temperature. Specimens were
washed, stained with unbuffered aqueous 1% osmium tetroxide
(BDH), dehydrated and embedded in araldite epoxy resin (Leica).
Semi-thin sections (0.5-1 μm) were cut on an Ultracut E ultra
microtome (Leica), stained with 1% Toluidine Blue (BDH), and
examined under a Dialux light microscope. Ultra-thin sections (70-
100 nm) were collected on copper grids, stained with uranyl acetate
and lead citrate (BDH), and examined under a JEOL JEM1230
transmission electron microscope. Neuron cells from a 145100
μm area of the sciatic nerve cross section were counted and
analysed using a Student’s two-tailed t-test.
For dorsal and ventral spinal root morphometry studies, mice
on the C57BL/6 background were transcardially perfused, under
terminal pentobarbitone anaesthesia, with a fixative consisting of
3% gluaraldehyde in 0.05 M sodium cacodylate buffer at pH 7.4.
Right L4 and L5 dorsal root ganglia with the attached dorsal and
ventral roots were dissected, post-fixed in 1% osmium tetroxide
(Agar Scientific) and processed into araldite CY212 epoxy resin
(Agar Scientific) through graded alcohols and propylene oxide using
a standard protocol. Semi-thin sections (0.8 μm) were cut on an
Ultracut E ultra microtome (Leica), stained with 1% Toluidine Blue
containing 1% borax (BDH), and examined with a Dialux light
microscope. The saphenous nerve was immersion fixed for 5
minutes in dead mice, and a piece that was distal to the medial
articular nerve was taken, post fixed and processed as described
for the spinal roots.
The saphenous nerve (C57BL/6 background) and the L4 and L5
dorsal/ventral roots were photographed at a 40 magnification.
The number of myelinated axons and their area was measured using
Photoshop CS3 and axon diameter (excluding the myelin sheath)
was calculated assuming circularity. The density and total number
of myelinated axons were calculated from the images (145100
μm) and area measurements of the nerve/roots, respectively, using
a Leica Quantimet image analyser.
Samples of the hairy skin from the medial dorsum of the foot
of the hindlimb and from the glabrous skin of the hindpaw
(C57BL/6 background) were fixed in 4% PFA and 50 μm-thick
sections were cut on a cryostat. Free-floating sections were
immunostained for the panaxonal marker PGP9.5 using a rabbit
polyclonal antibody (1:500, Ultraclone, UK) and an anti-rabbit Alexa
Fluor 488-conjugated secondary antibody (IgG) (Invitrogen, UK)
and visualised on a Leica epifluorescence or a Zeiss 510 LSM
confocal microscope.
Assessment of muscle force and motor unit number
The maximum force of the TA and EDL muscles was assessed in
adult female N2 mice at 4 months of age. The animals were
anaesthetised (4.5% chloral hydrate solution, 1 ml/100 g body
weight, i.p.; Sigma-Aldrich, Poole, UK) and prepared for isometric
tension recordings of muscle contraction (Kieran and Greensmith,
2004). The distal tendons of the TA and EDL muscles were
exposed, dissected from the surrounding tissue, and cut. The
hindlimbs of the animals were then secured rigidly to the table
with stainless steel pins and the distal tendons of the TA and EDL
muscles were attached to an isometric force transducer
(Dynamometer UFI Devices) with silk thread. The sciatic nerve
was exposed and sectioned, and all branches were cut except for
the deep peroneal nerve that innervates the TA and EDL muscles.
The length of the muscles was adjusted for maximum twitch
tension. The muscles and nerves were kept moist with saline
throughout the recordings and all experiments were carried out
at room temperature (23°C). Isometric contractions were elicited
by stimulating the nerve to TA and EDL using square-wave pulses
with a duration of 0.02 milliseconds, and by supramaximal
intensity through platinum electrodes. Tetanic contractions were
dmm.biologists.org370
GARS mouseRESEARCH ARTICLE
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
elicited by trains of stimuli at a frequency of 40, 80 and 100 Hz.
Maximum twitch and tetanic tension, and time to peak and half-
relaxation time values were measured using a computer and
appropriate software (Scope). The number of motor units in both
EDL muscles was assessed by applying stimuli of increasing
intensity to the motor nerve, resulting in stepwise increments in
twitch tension, owing to the successive recruitment of motor
axons. The number of stepwise increments was counted to give
an estimate of the number of functional motor units present in
each muscle.
Fatigue test
At the end of the isometric tension recordings, the fatigue pattern
of the EDL muscles was assessed by repeatedly stimulating the
muscle at 40 Hz for 250 milliseconds every second for 3 minutes,
and the contractions were recorded on a pen recorder (Lectromed
multitrace 2, UK). EDL is normally a fast fatiguable muscle that
fatigues rapidly when stimulated repeatedly. From each fatigue
trace, the decrease in tension after 3 minutes of stimulation was
measured and a fatigue index (F.I.) was calculated: (initial tetanic
tension/tetanic tension after stimulation)/initial tetanic 
tension.
Muscle weight, histochemistry and morphometry
At the end of each in vivo physiology experiment, the TA and EDL
muscles (C57BL/6 background) were removed, weighed, snap
frozen in isopentane cooled in liquid nitrogen and stored at –80°C
until processing. Serial cross sections (10 μm) of TA and EDL
muscles were cut on a cryostat and stained for SDH activity to
determine the oxidative capacity of the muscle fibres, as described
previously (Kieran and Greensmith, 2004). TA and EDL muscle
sections were examined under a light microscope (Leica DMR)
using Leica HC PL Fluotar objectives (10, 20 and 40
magnification). The total number and CSA of mutant and wild-
type muscle fibres were calculated from SDH-stained muscle
sections. In addition, the total number of muscle fibres from three
sections from the belly of TA and EDL muscles from GarsC201R/+
mice (n=3) and wild-type littermate control mice (n=3) were
counted. For each muscle section, the CSA of ~2000 (±87) muscle
fibres (approximately 70% of the TA muscle) and ~350 (±51.2)
muscle fibres (approximately 50% of the EDL muscle) were
calculated by tracing around the fibre perimeters using Leica
software. The analysis of CSA of muscle fibres is more accurate in
exposing changes in fibre size than measuring other parameters
such as muscle fibre diameter (Gorio et al., 1983).
Motor neuron survival
Following removal of the hindlimb muscles, the mice (C57BL/6
background) were perfused transcardially with 4% PFA in 0.1 M
PBS. The lumbar region of the spinal cord was removed, post-fixed
in 4% PFA for 6 hours and cryoprotected in 30% sucrose for a
minimum of 8 hours. Serial transverse sections (20 μm) were cut
using a cryostat and stained with gallocyanin, a Nissl stain. Spinal
cord sections were examined under a light microscope (Leica
DMR) using Leica HC PL Fluotar objectives (10, 20 and 40
magnification). The numbers of Nissl-stained motor neurons in the
sciatic motor pool of every third section (n=60) between the L2 and
L5 levels of the spinal cord were counted. Only large (diameter >12
μm) polygonal neurons with a distinguishable nucleus and nucleolus
and a clearly identifiable Nissl structure were included in the
counts. Images were captured using a Nikon E995 digital camera
and the images were downloaded into Adobe Photoshop CS. To
optimise image contrast, ‘levels adjustment’ operations were
performed, but no other image manipulations were made.
Statistical analysis for muscle and motor neuron studies
Statistical significance among the groups was assessed using a
Mann-Whitney U-test, Student’s t-test and ANOVA. Significance
was set at P<0.05.
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Clinical issue
Charcot-Marie-Tooth (CMT) diseases are hereditary sensory neuropathies,
which affect up to 1 in 2500 individuals. They are characterised by distal
muscle weakness and impaired sensation. A related set of peripheral nervous
system disorders are the hereditary motor neuronopathies (HMNs), which lead
to muscle wasting and death in severe cases. These diseases are difficult to
model owing to phenotypic variance and the lethality of known mutations in
mice. Recently, mutations in a single gene, encoding the enzyme glycyl-tRNA
synthetase (GARS), were found in familial cases of both CMT and severe
infantile HMN. GARS function is ubiquitously important for protein translation,
where it is necessary to load glycine into proteins, but it is not clear why
mutations in the GARS gene result in neurological disease. New evidence
shows that the activity of GARS and other amino acid transport enzymes is
present in nerve terminal ends, away from the cell body where such activities
were thought to take place. Furthermore, several recent papers show that
mutations in other tRNA synthetases cause neurological effects. However, the
purpose of tRNA synthetase in neuron terminals is unknown and it is possible
that their undiscovered functions may contribute to neuropathy.
Results
We describe a new mouse model with a dominant mutation in the Gars gene,
which displays a spectrum of disorders reminiscent of disease in humans,
particularly the CMTs. The mutation has sensory effects, which include the loss
of electrical conductance in certain nerves and muscle abnormalities.
Although heterozygous mice have a relatively mild phenotype, these animals
have defects at the neuromuscular junction. Intriguingly, phenotypes vary
depending on the genetic background, concordant with a recent genetic
study, which identified that a single regulatory locus controls expression of
many of the tRNA synthetases in the mouse. Very few homozygous mice
survive to birth and all die within 17 days of birth. Still, this is the first report of
successful breeding of homozygous animals with this mutation, and the
unique access to material from homozygous animals allows for comparison of
enzyme levels and activities between wild-type, heterozygous and
homozygous animals. The authors’ findings suggest that, in addition to its role
in neuropathy, the GARS enzyme may be particularly important during
development.
Implications and future directions
This new mouse model shows many similarities to human mutations in GARS,
including phenotype variability, which in this study is influenced by the
unique genetic background of two different inbred mouse lines. This indicates
that other genes in the genome can modulate the GARS phenotype and that
the products of these genes may represent accessible targets for therapeutics.
The production of homozygous mice for study will enable the characterisation
of the GARS enzyme defects that contribute to human diseases such as CMT
and HMN, and the role of this enzyme during development and aging.
Furthermore, this model should provide insight into the contribution of other
tRNA synthetase defects on nervous system pathology.
doi:10.1242/dmm.003541
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Studies of neuromuscular junctions
Muscles were dissected, fixed by immersion in 2% buffered PFA,
and compressed and mildly teased before staining. Staining was
performed using a cocktail of anti-neurofilament (2H3), anti-SV2
(Developmental Studies Hybridoma Bank) and Alexa Fluor 594-
conjugated alpha-bungarotoxin (Invitrogen/Molecular Probes).
Images were collected on a Leica SP5 confocal microscope as serial
Z sections and projections are shown.
Sensory nerve conduction studies
SNAPs of the Aβ- and C-fibres were recorded in the saphenous
skin nerve in vitro preparation (C57BL/6 background), as described
previously (Koltzenburg et al., 1997; Maurer et al., 2007). The skin
of the hindlimb, with the saphenous nerve attached, was removed
and mounted corium-side up in an organ bath (Fig. 6A) and
superfused with synthetic interstitial fluid (SIF) consisting of (in
mM): 108 NaCl, 3.48 KCl, 3.5 MgSO4, 26 NaHCO3, 1.5 CaCl2, 9.6
sodium gluconate, 5.55 glucose, 7.6 sucrose and 10 HEPES, titrated
with NaOH to pH 7.4. The temperature of the bath was maintained
at 32°C and continually gassed with oxygen. The proximal end of
the nerve was desheathed and positioned in a separate recording
chamber filled with liquid paraffin. Recordings were obtained in
common rejection mode using gold wire electrodes. A self-sealing
stainless steel ring was placed on top of the saphenous nerve and
the SIF replaced by paraffin oil. The whole nerve was stimulated
using non-polarisable Ag/AgCl electrodes, with the cathode
positioned in the ring and the anode outside in the organ bath.
Compound action potentials were recorded with an isolated
custom-made amplifier, using an amplification of 1000-10,000,
and using a 1 Hz high-pass filter and a 1 kHz low-pass filter. The
amplitude of the SNAP was measured peak-to-peak, and
conduction velocity was determined as the distance between the
stimulating and recording electrodes divided by the latency to the
beginning of the negative peak of the SNAP. We measured several
parameters of nerve excitability including the strength-duration
time constant, recovery of excitability after a supramaximal stimuli,
and accommodation to conditioning subthreshold polarising
stimuli, such as threshold electrotonus or the current-threshold
relationship (supplementary material Fig. S5). All values are
expressed as mean±s.e.m. and are compared statistically using
unpaired t-tests.
ACKNOWLEDGEMENTS
This work was supported by the Amyotrophic Lateral Sclerosis Association (V.B.-F.,
L.G., E.M.C.F.); Brain Research Trust (R.C., L.G., E.M.C.F.); European Commission Sixth
Framework Programme NEST-2003-1 Adventure Programme12702 (J.v.M., M.K.);
Medical Research Council (UK) (V.T., P.M.N.); UK MRC Centre for Neuromuscular
Disease (M.A.-Q., S.B., M.K., L.G., E.M.C.F.; G0500288 to E.M.C.F.); Motor Neuron
Disease Association (F.A., J.E.M., E.M.C.F.); National Institutes of Health NS054154
(R.W.B.); Robert Packard Center for ALS Research at Johns Hopkins (V.B.-F., L.G.,
E.M.C.F.); Wellcome Trust (UK) 076700 (G.T.B., E.M.C.F.). We thank Debra Brooker,
David Dignam, Eriani Gilbert, Leslie Nangle, Zuzanna Tymowska-Lalanne, James
Stevens and Sara Wells for generous support with either mouse or enzyme
studies, and Ray Young for graphics. We are also grateful to Christiana Ruhrberg
for developmental analysis of heterozygous embryos. Deposited in PMC for
immediate release. This article is freely accessible online from the date of
publication.
COMPETING INTERESTS
The authors declare no competing financial interests.
AUTHOR CONTRIBUTIONS
Conceived and designed the experiments: F.A., V.B.-F., H.P.W., G.T.B., V.T., R.W.B., S.B.,
J.E.M., M.K., L.G., P.M.N. and E.M.C.F. Performed the experiments and analysed the
data: F.A., V.B.-F., H.P.W., G.T.B., M.A., R.C., V.T., M.G., C.D.N., K.L.S., R.K., J.v.M., R.W.B.,
S.B., J.E.M. and M.K. Contributed reagents/materials: M.Z.C. and K.T.
SUPPLEMENTARY INFORMATION
Supplementary material for this article is available at
http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.002527/-/DC1
Received 6 January 2009; Accepted 17 February 2009.
REFERENCES
Antonellis, A., Ellsworth, R. E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S.Q.,
Jordanova, A., Kremensky, I., Christodoulou, K., Middleton, L. T. et al. (2003).
Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal
spinal muscular atrophy type V. Am. J. Hum. Genet. 72, 1293-1299.
Antonellis, A., Lee-Lin, S. Q., Wasterlain, A., Leo, P., Quezado, M., Goldfarb, L. G.,
Myung, K., Burgess, S., Fischbeck, K. H. and Green, E. D. (2006). Functional
analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging
enzymes in peripheral axons. J. Neurosci. 26, 10397-10406.
Banks, G. T., Kuta, A., Isaacs, A. M. and Fisher, E. M. C. (2008). TDP-43 is a culprit in
human neurodegeneration and not just an innocent bystander. Mamm. Genome 19,
299-305.
Bostock, H. (2004). Nerve excitability studies: past, present, future? Suppl. Clin.
Neurophysiol. 57, 85-90.
Cader, M. Z., Ren, J., James, P. A., Bird, L. E., Talbot, K. and Stammers, D. K. (2007).
Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase: an
enzyme underlying distal spinal muscular atrophy. FEBS Lett. 581, 2959-2964.
Chihara, T., Luginbuhl, D. and Luo, L. (2007). Cytoplasmic and mitochondrial protein
translation in axonal and dendritic terminal arborization. Nat. Neurosci. 10, 828-837.
Del Bo, R., Locatelli, F., Corti, S., Scarlato, M., Ghezzi, S., Prelle, A., Fagiolari, G.,
Moggio, M., Carpo, M., Bresolin, N. et al. (2006). Coexistence of CMT-2D and distal
SMA-V phenotypes in an Italian family with a GARS gene mutation. Neurology 66,
752-754.
Dignam, S. S. and Dignam, J. D. (1984). Glycyl- and alanyl-tRNA synthetases from
Bombyx mori: purification and properties. J. Biol. Chem. 259, 4043-4048.
Dubourg, O., Azzedine, H., Yaou, R. B., Pouget, J., Barois, A., Meininger, V.,
Bouteiller, D., Ruberg, M., Brice, A. and LeGuern, E. (2006). The G526R glycyl-tRNA
synthetase gene mutation in distal hereditary motor neuropathy type V. Neurology
66, 1721-1726.
Edvardson, S., Shaag, A., Kolesnikova, O., Gomori, J. M., Tarassov, I., Einbinder, T.,
Saada, A. and Elpeleg, O. (2007). Deleterious mutation in the mitochondrial arginyl-
transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am. J.
Hum. Genet. 81, 857-862.
Giuditta, A., Kaplan, B. B., van Minnen, J., Alvarez, J. and Koenig, E. (2002). Axonal
and presynaptic protein synthesis: new insights into the biology of the neuron.
Trends Neurosci. 25, 400-404.
Gorio, A., Carmignoto, G., Finesso, M., Polato, P. and Nunzi, M. G. (1983). Muscle
reinnervation. II. Sprouting, synapse formation and repression. Neuroscience 8, 403-
416.
James, P. A., Cader, M. Z., Muntoni, F., Childs, A. M., Crow, Y. J. and Talbot, K.
(2006). Severe childhood SMA and axonal CMT due to anticodon binding domain
mutations in the GARS gene. Neurology 67, 1710-1712.
Jia, J., Arif, A., Ray, P. S. and Fox, P. L. (2008). WHEP domains direct noncanonical
function of glutamyl-Prolyl tRNA synthetase in translational control of gene
expression. Mol. Cell 29, 679-690.
Jordanova, A., Irobi, J., Thomas, F. P., Van Dijck, P., Meerschaert, K., Dewil, M.,
Dierick, I., Jacobs, A., De Vriendt, E., Guergueltcheva, V. et al. (2006). Disrupted
function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant
intermediate Charcot-Marie-Tooth neuropathy. Nat. Genet. 38, 197-202.
Kieran, D. and Greensmith, L. (2004). Inhibition of calpains, by treatment with
leupeptin, improves motoneuron survival and muscle function in models of
motoneuron degeneration. Neuroscience 125, 427-439.
Koltzenburg, M., Stucky, C. L. and Lewin, G. R. (1997). Receptive properties of mouse
sensory neurons innervating hairy skin. J. Neurophysiol. 78, 1841-1850.
Lee, J. W., Beebe, K., Nangle, L. A., Jang, J., Longo-Guess, C. M., Cook, S. A.,
Davisson, M. T., Sundberg, J. P., Schimmel, P. and Ackerman, S. L. (2006). Editing-
defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature
443, 50-55.
Li, S., Finley, J., Liu, Z. J., Qiu, S. H., Chen, H., Luan, C. H., Carson, M., Tsao, J.,
Johnson, D., Lin, G. et al. (2002). Crystal structure of the cytoskeleton-associated
protein glycine-rich (CAP-Gly) domain. J. Biol. Chem. 277, 48596-48601.
Lin, A. C. and Holt, C. E. (2007). Local translation and directional steering in axons.
EMBO J. 26, 3729-3736.
Martin, N., Jaubert, J., Gounon, P., Salido, E., Haase, G., Szatanik, M. and Guenet, J.
L. (2002). A missense mutation in Tbce causes progressive motor neuronopathy in
mice. Nat. Genet. 32, 443-447.
dmm.biologists.org372
GARS mouseRESEARCH ARTICLE
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Maurer, K., Bostock, H. and Koltzenburg, M. (2007). A rat in vitro model for the
measurement of multiple excitability properties of cutaneous axons. Clin.
Neurophysiol. 118, 2402-2412.
Mozhui, K., Ciobanu, D. C., Schikorski, T., Wang, X., Lu, L. and Williams, R. W.
(2008). Dissection of a QTL hotspot on mouse distal chromosome 1 that modulates
neurobehavioral phenotypes and gene expression. PLoS Genet. 4, e1000260.
Nangle, L. A., Motta, C. M. and Schimmel, P. (2006). Global effects of mistranslation
from an editing defect in mammalian cells. Chem. Biol. 13, 1091-1100.
Nangle, L. A., Zhang, W., Xie, W., Yang, X. L. and Schimmel, P. (2007). Charcot-
Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer
interface and neurite distribution defect. Proc. Natl. Acad. Sci. USA 104, 11239-
11244.
Nolan, P. M., Peters, J., Strivens, M., Rogers, D., Hagan, J., Spurr, N., Gray, I. C.,
Vizor, L., Brooker, D., Whitehill, E. et al. (2000). A systematic, genome-wide,
phenotype-driven mutagenesis programme for gene function studies in the mouse.
Nat. Genet. 25, 440-443.
Park, S. G., Ewalt, K. L. and Kim, S. (2005). Functional expansion of aminoacyl-tRNA
synthetases and their interacting factors: new perspectives on housekeepers. Trends
Biochem. Sci. 30, 569-574.
Park, S. G., Schimmel, P. and Kim, S. (2008). Aminoacyl tRNA synthetases and their
connections to disease. Proc. Natl. Acad. Sci. USA 105, 11043-11049.
Puls, I., Jonnakuty, C., LaMonte, B. H., Holzbaur, E. L., Tokito, M., Mann, E., Floeter,
M. K., Bidus, K., Drayna, D., Oh, S. J. et al. (2003). Mutant dynactin in motor
neuron disease. Nat. Genet. 33, 455-456.
Ribas de Pouplana, L. and Geslain, R. (2008). Not just because it is there: aminoacyl-
tRNA synthetases gain control of the cell. Mol. Cell 30, 3-4.
Rogers, D. C., Fisher, E. M., Brown, S. D., Peters, J., Hunter, A. J. and Martin, J. E.
(1997). Behavioral and functional analysis of mouse phenotype: SHIRPA, a
proposed protocol for comprehensive phenotype assessment. Mamm. Genome 8,
711-713.
Rogers, D. C., Peters, J., Martin, J. E., Ball, S., Nicholson, S. J., Witherden, A. S.,
Hafezparast, M., Latcham, J., Robinson, T. L., Quilter, C. A. et al. (2001). SHIRPA:
validation for longitudinal study of neurological dysfunction in mice. Neurosci. Lett.
306, 89-92.
Scheper, G. C., van der Klock, T., van Andel, R. J., van Berkel, C. G., Sissler, M., Smet,
J., Muravina, T. I., Serkov, S. V., Uziel, G., Bugiani, M. et al. (2007). Mitochondrial
aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem
and spinal cord involvement and lactate elevation. Nat. Genet. 39, 534-539.
Schwarz, J. R., Glassmeier, G., Cooper, E. C., Kao, T. C., Nodera, H., Tabuena, D.,
Kaji, R. and Bostock, H. (2006). KCNQ channels mediate IKs, a slow K+ current
regulating excitability in the rat node of Ranvier. J. Physiol. 573, 17-34.
Seburn, K. L., Nangle, L. A., Cox, G. A., Schimmel, P. and Burgess, R. W. (2006). An
active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a
Charcot-Marie-Tooth 2D mouse model. Neuron 51, 715-726.
Sharp, P. S., Dick, J. R. and Greensmith, L. (2005). The effect of peripheral nerve
injury on disease progression in the SOD1(G93A) mouse model of amyotrophic
lateral sclerosis. Neuroscience 130, 897-910.
Shiba, K., Schimmel, P., Motegi, H. and Noda, T. (1994). Human glycyl-tRNA
synthetase. Wide divergence of primary structure from bacterial counterpart and
species-specific aminoacylation. J. Biol. Chem. 269, 30049-30055.
Sivakumar, K., Kyriakides, T., Puls, I., Nicholson, G. A., Funalot, B., Antonellis, A.,
Sambuughin, N., Christodoulou, K., Beggs, J. L., Zamba-Papanicolaou, E. et al.
(2005). Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase
mutations. Brain 128, 2304-2314.
Skre, H. (1974). Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin.
Genet. 6, 98-118.
Tucci, V., Achilli, F., Blanco, G., Lad, H. V., Wells, S., Godinho, S. and Nolan, P. M.
(2007). Reaching and grasping phenotypes in the mouse (Mus musculus): a
characterization of inbred strains and mutant lines. Neuroscience 147, 573-582.
Weisbrich, A., Honnappa, S., Jaussi, R., Okhrimenko, O., Frey, D., Jelesarov, I.,
Akhmanova, A. and Steinmetz, M. O. (2007). Structure-function relationship of
CAP-Gly domains. Nat. Struct. Mol. Biol. 14, 959-967.
Williams, J., Osvath, S., Khong, T. F., Pearse, M. and Power, D. (1995). Cloning,
sequencing and bacterial expression of human glycine tRNA synthetase. Nucleic
Acids Res. 23, 1307-1310.
Xie, W., Nangle, L. A., Zhang, W., Schimmel, P. and Yang, X. L. (2007). Long-range
structural effects of a Charcot-Marie-Tooth disease-causing mutation in human
glycyl-tRNA synthetase. Proc. Natl. Acad. Sci. USA 104, 9976-9981.
Disease Models & Mechanisms 373
GARS mouse RESEARCH ARTICLE
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
